USDA’s Agricultural Research Service intends to grant to Huvepharma EOOD of Sofia, Bulgaria, an exclusive license for an experimental African swine fever vaccine. The vaccine claim was made in U.S. Patent No. 9,463,234, “Attenuated African swine fever virus strain induces protection against challenge with homologous virulent parental virus Georgia 2007 isolate,” issued on Oct. 11, 2016.
Comments must be received on or before May 22.
The prospective exclusive license will be royalty-bearing.The prospective exclusive license may be granted unless, within 30 days from the date of this published Notice, the ARS receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Based in Sofia, Huvepharma develops, manufactures and markets human and animal health products. Its products include anticoccidials, veterinary products, feed additives and medicated feed additives. The pharmaceutical company also manufactures and markets enzymes for food, feed and industrial applications.